Invivyd annual revenue
2022
2023
2024
2025
Invivyd Revenue Growth & History (IVVD)
Invivyd reported $53.4M in revenue for fiscal 2025, an increase of 110.47% from the previous fiscal year.
View full Invivyd company overviewInvivyd annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $53.4M | $28.0M | +110.47% |
| 2024 | 2024-12-31 | $25.4M | $25.4M | — |
| 2023 | 2023-12-31 | $0 | $0 | — |
| 2022 | 2022-12-31 | $0 | — | — |
Invivyd quarterly revenue
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.3M | $2.5M | +21.20% |
| Q1 2026 | 2026-03-31 | $13.7M | $2.4M | +21.59% |
| Q4 2025 | 2025-12-31 | $17.2M | $3.4M | +24.51% |
| Q3 2025 | 2025-09-30 | $13.1M | $3.8M | +41.17% |
| Q2 2025 | 2025-06-30 | $11.8M | $9.5M | +420.58% |
| Q1 2025 | 2025-03-31 | $11.3M | $11.3M | — |
| Q4 2024 | 2024-12-31 | $13.8M | — | — |
| Q3 2024 | 2024-09-30 | $9.3M | $9.3M | — |
| Q2 2024 | 2024-06-30 | $2.3M | $2.3M | — |
| Q1 2024 | 2024-03-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $0 | — | — |
| Q2 2023 | 2023-06-30 | $0 | — | — |
Invivyd revenue growth trends
Invivyd's latest reported quarter, Q2 2026, generated $14.3M in revenue, an increase of 21.20% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Invivyd source filings ↗Community posts
Invivyd reports favorable Phase 3 tolerability results and outlines filing plans
Invivyd ($IVVD) said its investigational antibody VYD2311 met the primary and key secondary safety endpoints in LIBERTY, a randomized study involving 210 healthy adults aged 18–49. Within six days, 56.5% of antibody recipients reported an a ...
